AIManage Using an AI-driven CDS and Chatbot

Starting soon · Not applicable

Conditions studied: Diabetes, Obesity, Medication Side Effects

In brief

The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH. The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).

Key facts

Study ID

NCT07546357

Run by

NYU Langone Health

People needed

16

Starts

2026-06-01

Expected to finish

2029-03-30

Last updated by the study team

2026-04-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provider Eligibility Criteria (Phase 1)
• Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics,
• Provide care to at least 5 patients prescribed an IMM.
• Patient Eligibility Criteria (Phase 1)
• (Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months;
• Fluency in English or Spanish;
• Be willing to send/receive text messages; and
• Be > 18 years of age.

You may not qualify if…

• Provider Exclusion Criteria (Phase 1) • Refuse to participate
• Patient Exclusion Criteria (Phase 1)
• Refuse or are unable to provide informed consent;

Where it is running

• NYU Langone Health — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.